Tiragolumab (TIGIT inhibitor) plus Atezolizumab shows promising Efficacy in PD-L1-positive advanced NSCLC
16467
post-template-default,single,single-post,postid-16467,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Tiragolumab (TIGIT inhibitor) plus Atezolizumab shows promising Efficacy in PD-L1-positive advanced NSCLC

Home > Blogs  > Tiragolumab (TIGIT inhibitor) plus Atezolizumab shows promising Efficacy in PD-L1-positive advanced NSCLC

31 May Tiragolumab (TIGIT inhibitor) plus Atezolizumab shows promising Efficacy in PD-L1-positive advanced NSCLC

Posted at 10:04h in Blogs by

In chemotherapy-naïve, PD-L1-positive (tumour proportion score ≥1%) patients with locally advanced or metastatic NSCLC, tiragolumab plus atezolizumab showed a significant improvement in both objective response rate (ORR) and progression-free survival (PFS), with a stratified hazard ratio 0·57 [95% CI 0·37–0·90], p=0·015.
The combination was well tolerated, with a safety profile similar to that of atezolizumab alone. (Cho BC et al. The lancet Oncology May 13, 2022)
#oncologyresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6937287219028070400

No Comments

Sorry, the comment form is closed at this time.